Moderna Reports Q1 2026 Revenue Jump to $389 Million Amid Global Expansion
Moderna (NASDAQ:MRNA) has reported a significant recovery in its first-quarter 2026 financial results, posting total revenue of $389 million. This represents an increase of $281 million compared to the first quarter of 2025, signaling a strategic shift as the company expands its footprint in international markets and diversifies its product portfolio.
While the revenue growth is a positive indicator, the company continues to navigate a challenging financial transition. Moderna reported a GAAP net loss of $1.3 billion for the quarter, with a GAAP earnings per share (EPS) of $(3.40). This loss was heavily influenced by a $0.9 billion non-recurring litigation settlement charge.
Global Markets Drive Revenue Growth
A critical component of Moderna’s current growth strategy is its pivot toward international markets. According to the company’s latest filings, approximately 80% of its first-quarter revenue was generated from international sales. This surge is largely attributed to the continued demand for its Covid-19 vaccine and the impact of two new product approvals in Europe.
The company is leveraging its mRNA platform to move beyond the pandemic-era reliance on a single product. By expanding its commercial reach globally, Moderna aims to stabilize its income streams as the U.S. Market for Covid-19 vaccines continues to evolve.
Financial Health and Future Outlook
Despite the quarterly net loss, Moderna maintains a substantial cash reserve to fund its research and development. As of March 31, 2026, the company reported cash and investments totaling $7.5 billion.
Looking ahead, Moderna has reiterated its 2026 financial targets, including a goal of up to 10% revenue growth. The company is also focused on aggressive cost-reduction measures to reach a cash break-even point, building on the operational discipline established throughout 2025.
Expanding the mRNA Pipeline
Moderna is currently advancing its pipeline to transition from a “one-product company” to a diversified biotechnology leader. Key areas of focus include:
- Respiratory Vaccines: The company anticipates potential first approvals for flu and flu/COVID combination products.
- Oncology: Moderna is advancing multiple oncology candidates, including individualized neoantigen therapies.
- Commercial Portfolio: The company now has three approved commercial products, providing a broader base for revenue generation.
- Total Revenue: $389 million (up $281 million YoY).
- Net Loss: $1.3 billion (includes a $0.9 billion one-time litigation charge).
- Revenue Source: ~80% derived from international markets.
- Liquidity: $7.5 billion in cash and investments as of March 31, 2026.
- Growth Target: Up to 10% revenue growth projected for 2026.
Frequently Asked Questions
Why did Moderna report a loss despite higher revenue?
The $1.3 billion GAAP net loss was primarily driven by a $0.9 billion non-recurring charge related to a litigation settlement. These one-time legal costs often mask the underlying operational performance of the company.
What is driving Moderna’s international sales?
Growth is being driven by international Covid-19 vaccine sales and the recent approval of new products in European markets, allowing the company to reduce its dependence on the U.S. Healthcare system.
What are the next major milestones for Moderna?
The company is awaiting regulatory decisions on its flu and combination flu/COVID vaccines, which would significantly expand its seasonal vaccine offering and recurring revenue potential.
As Moderna moves through 2026, the focus remains on balancing aggressive scientific innovation in oncology and respiratory health with the financial necessity of cost reduction and operational efficiency.